Saturday, March 18, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Featured News

BARDA Seeks Single Dose Anthrax Post-Exposure Vaccine

by Global Biodefense Staff
March 9, 2016
Bacillus Anthracis - Anthrax

The Biomedical Advanced Research and Development Authority (BARDA) is conducting research on market availability and capabilities for advanced development and manufacturing of next-generation anthrax vaccines.

The effort supports BARDA’s understanding of the current and future marketplace for planning purposes towards the possible procurement of Post-Exposure Prophylaxis (PEP) vaccines in the event of an anthrax biothreat event.

Anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillius anthracis, whichcan cause human disease via gastrointestinal, cutaneous, or inhalation routes.  The anthrax vaccine Biothrax® is currently licensed for PEP, however, it requires a three-dose vaccine regimen over 28 days to confer protection.

This three-dose requirement enhances the difficulty in delivery and adherence to the regimen amongst a civilian population in the event of a mass exposure. As such, BARDA is seeking a next-generation vaccine capable of reducing the number of vaccinations needed to confer protection post-exposure.

Characteristics of a new vaccine suitable for a PEP indication include rapid onset of protective immunity in one or two doses and capability for use in conjunction with antibiotics after exposure.

Improvements such as protection against all forms of anthrax, protection in special populations (children, elderly, and the immunocompromised), and elimination of cold chain storage would be considered additional enhancements for an ideal candidate.

Further details are available via Solicitation Number: BARDA-2016-Next-Generation-Anthrax-Vaccine-(01A). The RFI deadline is March 23, 2016.

Tags: AnthraxASPRBARDABioterrorismHHSRFIVaccines

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC